2019

1. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

   Arthritis and Rheumatology, Vol. 71, Núm. 10, pp. 1616-1625